» Articles » PMID: 23891641

Therapeutics of Alzheimer's Disease: Past, Present and Future

Overview
Specialties Neurology
Pharmacology
Date 2013 Jul 30
PMID 23891641
Citations 255
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential rise in the number of cases of AD, emphasizing the need for developing an effective treatment. AD also imposes tremendous emotional and financial burden to the patient's family and community. The disease has been studied over a century, but acetylcholinesterase inhibitors and memantine are the only drugs currently approved for its management. These drugs provide symptomatic improvement alone but do less to modify the disease process. The extensive insight into the molecular and cellular pathomechanism in AD over the past few decades has provided us significant progress in the understanding of the disease. A number of novel strategies that seek to modify the disease process have been developed. The major developments in this direction are the amyloid and tau based therapeutics, which could hold the key to treatment of AD in the near future. Several putative drugs have been thoroughly investigated in preclinical studies, but many of them have failed to produce results in the clinical scenario; therefore it is only prudent that lessons be learnt from the past mistakes. The current rationales and targets evaluated for therapeutic benefit in AD are reviewed in this article. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.

Citing Articles

Alkaloids from Caliphruria subedentata (Amaryllidaceae) as Regulators of AChE, BuChE, NMDA and GSK3 Activity: An In Vitro and In Silico Approach for Mimicking Alzheimer´s Disease.

Ordonez W, Palomino N, Varela P, Martinez I, Alves L, Giuliatti S Neurochem Res. 2025; 50(2):116.

PMID: 40056267 PMC: 11890331. DOI: 10.1007/s11064-025-04354-6.


Pathway-based network medicine identifies novel natural products for Alzheimer's disease.

Liang Y, Xie S, Jia J Alzheimers Res Ther. 2025; 17(1):43.

PMID: 39953559 PMC: 11829514. DOI: 10.1186/s13195-025-01694-x.


Aftereffect of single transcranial direct and alternating current stimulation on spontaneous home-cage and open-field EEG activities in a mouse model of Alzheimer's disease.

Sun H, Wang Y, Yuan D, Duan M, Chen Z, Fu Y Front Aging Neurosci. 2024; 16:1492838.

PMID: 39737333 PMC: 11683110. DOI: 10.3389/fnagi.2024.1492838.


Effect of Linalool, Cineole, and β-Bourbonene Coupled with Aerobic Training on the Improvement of Presenilin-1/Amyloid Protein Precursor/Interleukin-1 beta/CASPASE 1 Network, Oxidative Capacity, and miRNA-210 in Mice with Alzheimer's Disease.

Alimoradi Z, Taghian F, Jalali Dehkordi K Arch Razi Inst. 2024; 79(3):629-638.

PMID: 39736946 PMC: 11682515. DOI: 10.32592/ARI.2024.79.3.629.


Effects of cilostazol on cognitive function and dementia risk: A systematic review and meta-analysis.

Cheng X, Ren Q, Zhi J, Chen Q, Luo K, Yu L Medicine (Baltimore). 2024; 103(50):e40668.

PMID: 39686486 PMC: 11651509. DOI: 10.1097/MD.0000000000040668.